Johnson & Johnson Stock: Valuation Concerns Amid Strong Growth

Johnson & Johnson (JNJ) has had a remarkable year so far in 2023, delivering a 28% total return and outperforming both the S&P 500 ETF (SPY) and the Health Care SPDR (XLV). Despite its strong performance, the stock is now trading at a premium valuation. The company's solid Q2 results and raised FY 2026 guidance are expected to drive further growth.

However, several key risks remain, including MedTech growth softness, ongoing litigation, and macro uncertainties. These factors have led some analysts to question whether the stock is fully priced at its current levels. From a technical standpoint, JNJ remains in an uptrend but shows signs of potential near-term consolidation due to negative RSI divergence and valuation concerns.